My Portfolio
+
LINK YOUR PORTFOLIO

Coherus Oncology Inc CHRS:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 06/03/26 EDT
1.47quote price arrow down-0.05 (-3.29%)
Volume
1,029,930
52 week range
0.71 - 2.62
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close1.47
  • 52 Week High2.62
  • 52 Week High Date01/27/26
  • 52 Week Low0.71
  • 52 Week Low Date06/23/25

Latest On Coherus Oncology Inc

 

Key Stats

  • Market Cap226.747M
  • Shares Out154.25M
  • 10 Day Average Volume1.06M
  • Dividend-
  • Dividend Yield-
  • Beta0.96

Latest On Coherus Oncology Inc

 

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close1.47
  • 52 Week High2.62
  • 52 Week High Date01/27/26
  • 52 Week Low0.71
  • 52 Week Low Date06/23/25
  • Market Cap226.747M
  • Shares Out154.25M
  • 10 Day Average Volume1.06M
  • Dividend-
  • Dividend Yield-
  • Beta0.96

RATIOS/PROFITABILITY

  • EPS (TTM)-1.43
  • P/E (TTM)-1.03
  • Fwd P/E (NTM)-2.11
  • EBITDA (TTM)-159.653M
  • ROE (TTM)-860.65%
  • Revenue (TTM)46.883M
  • Gross Margin (TTM)68.06%
  • Net Margin (TTM)-368.28%
  • Debt To Equity (MRQ)65.53%

EVENTS

  • Earnings Date08/05/2026(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Profile

MORE
Coherus Oncology, Inc., formerly Coherus BioSciences, Inc., is a fully integrated commercial-stage oncology company with an approved PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. LOQTORZI (toripalimab-tpzi) is its immuno-oncology franchise. LOQTORZI is the FDA-approved treatment indicated in combination with chemotherapy for recurrent or metastatic nasopharyngeal carcinoma (NPC)...
Dennis Lanfear
Chairman of the Board, President, Chief Executive Officer
Bryan Mcmichael
Chief Financial Officer
Address
C/O DENNIS M. LANFEAR
201 REDWOOD SHORES PARKWAY, SUITE 200
Redwood City, CA
94065
United States